
Precipio PRPO
€ 22.54
1.64%
Geschäftsbericht 2025
hinzugefügt 30.03.2026
Precipio Langfristige Verbindlichkeiten 2011-2026 | PRPO
Langfristige Verbindlichkeiten Jährlich Precipio
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | 1.9 M | 1.97 M | 1.72 M | 4.2 M | 785 K | 655 K | 12.3 M | 10.2 M | 1.99 M | 6.19 M |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 12.3 M | 655 K | 4.19 M |
Langfristige Verbindlichkeiten anderer Aktien in der Diagnostik & Forschung
| Name | Langfristige Verbindlichkeiten | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
Centogene N.V.
CNTG
|
23.7 M | - | -6.23 % | $ 30.6 M | ||
|
Charles River Laboratories International
CRL
|
2.35 B | $ 168.22 | -3.26 % | $ 8.34 B | ||
|
Agilent Technologies
A
|
3.29 B | $ 114.84 | -0.55 % | $ 34.9 B | ||
|
Castle Biosciences
CSTL
|
2.76 M | $ 24.73 | -0.44 % | $ 687 M | ||
|
Danaher Corporation
DHR
|
26.9 B | $ 192.12 | 0.53 % | $ 137 B | ||
|
DexCom
DXCM
|
1.15 B | $ 63.21 | 1.59 % | $ 24.7 B | ||
|
Aspira Women's Health
AWH
|
3.49 M | - | -6.19 % | $ 10.5 M | ||
|
Biocept
BIOC
|
11.3 M | - | -13.05 % | $ 7.29 M | ||
|
Fulgent Genetics
FLGT
|
2.26 M | $ 16.42 | -2.38 % | $ 496 M | ||
|
Check-Cap Ltd.
CHEK
|
16 K | - | - | $ 9.42 M | ||
|
Guardant Health
GH
|
91.4 M | $ 89.66 | -4.44 % | $ 11.2 B | ||
|
Oxford Immunotec Global PLC
OXFD
|
7.74 M | - | - | $ 562 M | ||
|
Akumin
AKU
|
527 M | - | -17.87 % | $ 25.9 M | ||
|
ICON Public Limited Company
ICLR
|
461 M | $ 109.62 | -4.0 % | $ 9.04 B | ||
|
CareDx, Inc
CDNA
|
17.9 M | $ 17.82 | -2.68 % | $ 950 M | ||
|
Illumina
ILMN
|
2.04 B | $ 127.74 | 0.28 % | $ 20.3 B | ||
|
Burning Rock Biotech Limited
BNR
|
61.1 M | $ 16.3 | 0.62 % | $ 175 M | ||
|
IQVIA Holdings
IQV
|
13 B | $ 170.72 | -1.47 % | $ 29.3 B | ||
|
Accelerate Diagnostics
AXDX
|
134 M | - | -61.36 % | $ 2.46 M | ||
|
Laboratory Corporation of America Holdings
LH
|
7.82 B | $ 274.46 | 0.27 % | $ 22.8 B | ||
|
Lantheus Holdings
LNTH
|
225 M | $ 75.89 | -0.28 % | $ 5.12 B | ||
|
Global Cord Blood Corporation
CO
|
2.53 B | - | - | $ 399 M | ||
|
Fluidigm Corporation
FLDM
|
131 M | - | 1.08 % | $ 308 M | ||
|
Genetic Technologies Limited
GENE
|
559 K | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
48.5 M | - | 0.12 % | $ 80.1 M | ||
|
Exact Sciences Corporation
EXAS
|
981 M | - | - | $ 19.8 B | ||
|
Medpace Holdings
MEDP
|
73.8 M | $ 496.0 | -0.47 % | $ 14.3 B | ||
|
PRA Health Sciences, Inc.
PRAH
|
1.43 B | - | - | $ 10.7 B | ||
|
Mettler-Toledo International
MTD
|
1.61 B | $ 1 266.63 | 0.53 % | $ 26.1 B | ||
|
Myriad Genetics
MYGN
|
107 M | $ 4.67 | -1.68 % | $ 432 M | ||
|
ENDRA Life Sciences
NDRA
|
843 K | $ 4.74 | 1.07 % | $ 3.73 M | ||
|
NeoGenomics
NEO
|
435 M | $ 8.02 | 0.25 % | $ 1.03 B | ||
|
Neogen Corporation
NEOG
|
19.6 M | $ 9.56 | 1.59 % | $ 2.07 B | ||
|
DermTech
DMTK
|
865 K | - | -11.32 % | $ 2.94 M | ||
|
National Research Corporation
NRC
|
39.6 M | $ 17.33 | 0.99 % | $ 388 M | ||
|
Natera
NTRA
|
124 M | $ 204.87 | -1.5 % | $ 20.2 B | ||
|
Biodesix
BDSX
|
62.1 M | $ 15.36 | 1.92 % | $ 1.99 B | ||
|
Enzo Biochem
ENZ
|
4.6 M | - | -8.98 % | $ 14.8 K | ||
|
Pacific Biosciences of California
PACB
|
43.9 M | $ 1.42 | 5.97 % | $ 426 M | ||
|
Koninklijke Philips N.V.
PHG
|
8.08 B | $ 27.2 | 0.33 % | $ 20 B | ||
|
Personalis
PSNL
|
639 K | $ 6.58 | - | $ 390 M | ||
|
RadNet
RDNT
|
1.09 B | $ 55.06 | 0.49 % | $ 4.14 B | ||
|
Senseonics Holdings
SENS
|
163 M | $ 6.69 | -3.04 % | $ 279 M | ||
|
Sotera Health Company
SHC
|
3.1 B | $ 14.87 | -0.6 % | $ 4.22 B | ||
|
Heska Corporation
HSKA
|
57.9 M | - | - | $ 1.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
4.1 M | - | -20.0 % | $ 1.06 M | ||
|
Soleno Therapeutics
SLNO
|
10.8 M | $ 52.25 | 32.31 % | $ 2.66 B | ||
|
Neuronetics
STIM
|
24.6 M | $ 1.76 | 15.79 % | $ 116 M | ||
|
Thermo Fisher Scientific
TMO
|
22.5 B | $ 488.19 | -0.67 % | $ 184 B |